

1 **Title:** Gargle sample is an effective option in a novel fully automated molecular point-of-care
2 test for influenza: a multicenter study

3

4 **Short running head:** A novel molecular test for influenza

5

6 **Authors:**

7 Norihito Kaku ^{a,b, c#*}, Tomohito Urabe ^d, Tetsuya Iida ^e, Chyuns Yun ^f, Yoshiyuki Nishida ^g,
8 Yasunori Onitsuka ^h, Kohji Hashiguchi ⁱ, Kiyoto Hirose ^j, Akimitsu Tomonaga ^k, Koichi
9 Izumikawa ^l, Hiroshi Mukae ^m, Katsunori Yanagihara ^{a,b}

10

11 **Affiliations:**

12 ^a Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical
13 Sciences, Nagasaki City, Nagasaki, Japan

14 ^b Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki,
15 Japan

16 ^c Division of Pulmonary & Critical Care Medicine, University of Michigan, Michigan, Ann
17 Arbor, Michigan, USA

18 ^d Urabe Otorhinolaryngology Clinic, Nagasaki City, Nagasaki, Japan

19 ^e Iida Naika Syounika Clinic, Nagasaki City, Nagasaki, Japan

20 ^f Ohisama Pediatric Clinic, Nagayo-cho, Nagasaki, Japan

21 ^g Nishida Gastrointestinal Internal Medicine Clinic, Nagasaki City, Nagasaki, Japan

22 ^h Onitsuka Internal Medicine Clinic, Nagasaki City, Nagasaki, Japan

23 ⁱ Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital,

24 Nagasaki City, Nagasaki, Japan

25 ^jHirose Clinic, Nagasaki City, Nagasaki, Japan

26 ^kTomonaga Medical Clinic, Omura City, Nagasaki, Japan

27 ^lDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical
28 Sciences, Nagasaki City, Nagasaki, Japan

29 ^mDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical
30 Sciences, Nagasaki City, Nagasaki, Japan

31

32 #Address correspondence to Norihito Kaku, norihitk@gmail.com

33 *Address: Department of Laboratory Medicine, Nagasaki University Graduate School of
34 Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

35 Tel: +81-85-819-7574

36 Fax: +81-95-819-7422

37 *Present address:

38 Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University
39 of Michigan, 4438 BSRB, 109 Zina Pitcher Pl, Ann Arbor, Michigan 48109, USA

40

41 **Abstract**

42 **Background:** We conducted a multicenter study to evaluate the performance of a novel fully
43 automated molecular point-of-care test using transcription-reverse transcription concerted
44 reaction that can detect influenza A and B within 15 minutes in nasopharyngeal swabs and gargle
45 samples (TRCsatFLU).

46 **Methods:** Patients who visited or were hospitalized at eight clinics and hospitals with influenza-
47 like illnesses between December 2019 and March 2020 participated in this study. We collected
48 nasopharyngeal swabs from all patients and gargle samples from patients whom the physician
49 judged fit to perform gargling. The result of TRCsatFLU was compared to a conventional
50 reverse transcription-polymerase chain reaction (RT-PCR). If the results of TRCsatFLU and
51 conventional RT-PCR were different, the samples were analyzed by sequencing.

52 **Results:** We evaluated 233 nasopharyngeal swabs and 213 gargle samples from 244 patients.

53 . The average age of the patients was 39.3 ± 21.2 . Of the patients, 68.9% visited a hospital within
54 24 h of symptom onset. The most common symptoms were fever (93.0%), fatigue (79.5%), and
55 nasal discharge (64.8%). All patients in whom the gargle sample was not collected were children.
56 Influenza A or B was detected in 98 and 99 patients in nasopharyngeal swabs and gargle samples
57 using TRCsatFLU, respectively. Four and five patients in nasopharyngeal swabs and gargle
58 samples, respectively, with different TRCsatFLU and conventional RT-PCR results. Influenza A
59 or B was detected using sequencing in all samples with different results. Based on the combined
60 conventional RT-PCR and sequencing results, the sensitivity, specificity, positive predictive
61 value (PPV), and negative predictive value (NPV) of TRCsatFLU for influenza detection in
62 nasopharyngeal swabs were 0.990, 1.000, 1.000, and 0.993, respectively. In the gargle samples,
63 the sensitivity, specificity, PPV, and NPV of the TRCsatFLU for detecting influenza were 0.971,

64 1.000, 1.000, and 0.974, respectively.

65 **Conclusions:** The TRCsatFLU showed great sensitivity and specificity for the detection of
66 influenza in nasopharyngeal swabs and gargle samples.

67 **Trial registration:** This study was registered in the UMIN Clinical Trials Registry (reference
68 number: UMIN000038276) on October 11, 2019. Before sample collection, written informed
69 consent for the participation and publication of this study was obtained from all participants.

70

71 **Keywords:** rapid detection; influenza; TRC method; RT-PCR

72 **Background**

73 Influenza is a major infectious disease that spreads during the winter with clinics receiving
74 many influenza patients during the flu season. As antiviral agents for influenza, such as
75 neuraminidase inhibitors are already available, it is essential to accurately test and diagnose
76 influenza. Rapid influenza diagnostic tests (RIDTs) have been widely used in clinics because of
77 their simplicity and speed. However, they often have low sensitivity, especially in the early stage
78 of influenza, compared to nucleic acid tests. [1] Therefore, molecular point-of-care (POC) tests
79 and highly sensitive automated immunochromatographic antigen tests (digital immunoassays,
80 DIAs) for influenza have been developed and showed markedly higher sensitivities than
81 traditional rapid influenza diagnostic tests.[2] Recently, applying transcription-reverse
82 transcription concerted reaction (TRC), a novel fully automated molecular POC machine
83 (TRCsat®; Tosoh, Tokyo, Japan) with a dedicated single-use cartridge for influenza
84 (TRCsatFLU; Tosoh, Tokyo, Japan) was developed. TRC is a gene-detecting method that
85 involves rapid isothermal RNA amplification using an intercalation-activating fluorescence
86 (INAF) probe, and It has been used to diagnose tuberculosis, nontuberculous mycobacterial
87 infections, mycoplasma pneumonia, chlamydial infections, and gonorrhoea. [3,4] TRCsatFLU
88 contains all the elements required for detecting influenza A and B, and it can detect influenza A
89 and B within 15 min. One feature of TRCsatFLU, apart from other POC molecular tests, is that
90 it can detect influenza from gargle samples in addition to nasopharyngeal swabs with simple
91 sample preparation without purification. In a previous single-center study, TRCsatFLU showed
92 comparable performance to the conventional reverse transcription-polymerase chain reaction
93 (RT-PCR) method for detecting influenza viruses in nasopharyngeal swabs and gargle samples
94 obtained from patients with influenza-like illness (ILI). [5] However, in a previous study, we

95 divided the study period into two and collected gargle samples only from the second period. In
96 addition, because the study was conducted in only a secondary hospital where many adult
97 patients with underlying diseases were seen, it is unclear whether TRCsatFLU could show the
98 same results in patients with ILI, including children, who visit clinics. Therefore, we conducted a
99 multicenter study in several clinical settings, including pediatric clinics, to evaluate the
100 performance of TRCsatFLU for detecting influenza viruses in nasopharyngeal swabs and gargle
101 samples.

102

103 **Methods**

104 *Study design*

105 This prospective observational study was conducted between December 16, 2019 and March
106 25, 2020. The original plan was to collect samples until May 31, 2022 but the study was
107 suspended early on March 25, 2020 when the spread of coronavirus disease 2019 (COVID-19)
108 began in Japan. [6–8] Due to the continued COVID-19 pandemic, the study was not resumed,
109 and the analysis was conducted on the samples collected by March 25, 2020. We selected seven
110 internal medicine clinics, pediatrics, and otorhinolaryngology clinics in Nagasaki Prefecture that
111 could participate, the Urabe Otorhinolaryngology Clinic, Iida Naika Syounika Clinic, Ohisama
112 Pediatric Clinic, Nishida Gastrointestinal Intermedicine Clinic, Onitsuka Internal Medicine
113 Clinic, Hirose Clinic, and Tomonaga Medical Clinic. We also included a hospital that
114 participated in the previous study, the Japanese Red Cross Nagasaki Genbaku Hospital. In eight
115 medical facilities, we included patients who visited or were hospitalized with influenza-like
116 illness (ILI), as defined by the World Health Organization’s case definition.[9] Patients were
117 excluded if they were administered anti-influenza agents within one month before sampling.

118 After obtaining informed consent, nasopharyngeal swabs and gargle samples were collected.
119 Two nasopharyngeal swabs (1PY1502P; Japan Cotton Swab Industry, Limited, Tokyo, Japan)
120 were collected from all the patients by a healthcare provider. Gargle samples were collected from
121 patients whom the physician judged to be able to perform gargling. In gargle samples, the
122 patients gargled for 5 seconds with 20 mL of water (water for injection; Hikari Pharmaceutical
123 CO., LTD. Tokyo, Japan), which was collected. Gargle samples were stored at -20°C in a
124 container (Multi-purpose container, 70 mL; Sarstedt, K.K., Tokyo, Japan) until further analysis.
125 One of the swabs was used in each medical facility for detecting influenza by DIAs using silver
126 amplification immunochromatography (FUJI DRI-CHEM IMMUNO AG Cartridge FluAB;
127 Fujifilm, Kanagawa, Japan)[10], according to manufacturer's instruction. Another
128 nasopharyngeal swab and gargle samples were stored at -20°C in a sealable tube (PP screw cap
129 test tube; Maruemu Corporation, Osaka, Japan) without media until further analysis. The
130 physicians determined the clinical diagnosis based on medical history, physical findings, and
131 DIAs results, from which they produced a clinical report for each patient. Since TRCsatFLU was
132 not approved in Japan when this study was conducted, and it was necessary to prevent the use of
133 TRCsatFLU results for the diagnosis of influenza at medical facilities, nasopharyngeal swabs
134 and gargle samples were transferred to Tosoh Corporation for performing TRCsatFLU and RT-
135 PCR. All information, such as clinical report forms and TRCsatFLU and RT-PCR results, was
136 summarized and analyzed at Nagasaki University Hospital. If the results of TRCsatFLU were
137 different from those of RT-PCR, the samples were analyzed by sequencing at Tosoh Corporation.

138

139 *Ethics*

140 This study was approved by the ethics committee of Nagasaki University Hospital (approval

141 number:19121603) and registered in the UMIN Clinical Trials Registry (reference number:
142 UMIN000038276). Before sample collection, written informed consent for the participation and
143 publication of this study was obtained from all participants.

144

145 *Data collection*

146 To compile data on patient characteristics, we collected information on sex, age, underlying
147 diseases, history of influenza vaccination, time since onset of symptoms, body temperature at the
148 time of consultation, clinical diagnosis, results of DIAs, treatment for ILI, and the following
149 signs and symptoms: fever (body temperature ≥ 37.5 °C), cough, sore throat, nasal discharge,
150 headache, arthralgia and myalgia, fatigue, nausea, and diarrhea.

151

152 *TRC*

153 For TRCsatFLU, we soaked a new swab in a gargle sample for 5 sec, and the swab containing
154 the gargle solution was mixed with 1 mL extraction buffer containing surfactant, and it was
155 infected into a single-use cartridge that contains all the elements required for rapid TRC.
156 Nasopharyngeal swabs were mixed with 1 mL extraction buffer containing surfactant. Of the
157 extraction buffer, 140 μ L was aliquoted for RT-PCR, and the remaining 860 μ L was injected into
158 the TRCsatFLU cartridge. Next, the cartridge was set in TRCsat®, and nucleic acid
159 amplification, detection, and determination of results were automatically performed in the
160 instrument. The procedure of rapid TRC in TRCsat® is as follows: the samples were incubated
161 at 52 °C for 1 min and then mixed 30 μ L of the sample with a dry reagent containing enzymes,
162 substrates, primers, and INAF probes and incubated at 46 °C to monitor fluorescence; it was
163 automatically determined as positive when the fluorescence intensity ratio of the reaction

164 solution exceeded 1.2. TRCsatFLU was designed to detect Influenza A(H1N1), A(H1N1)pdm09,
165 A (H3N2), and B (Victoria and Yamagata lineages), but TRCsat® only showed the results with
166 influenza A or B positive or influenza negative.

167

168 *RT-PCR and sequencing*

169 We performed RNA extraction and RT-PCR according to the Influenza Diagnosis Manual 4th
170 edition (National Institute of Infectious Diseases, 2019).[11] In gargle samples, total RNA was
171 isolated from 140 µL of a gargle sample using a QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
172 Germany). For nasopharyngeal swabs, total RNA was isolated from 140 µL of the extraction
173 buffer using a QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). RT-PCR was
174 performed using the primers and probes listed in Table S1, the One-Step PrimeScript™ RT-PCR
175 Kit (TAKARA BIO, Shiga, Japan), and QuantStudio5 Real-Time PCR System (Thermo Fisher
176 Scientific, Massachusetts, USA). In brief, 2 µL of extracted RNA was added to 10 µL of 2X One
177 Step RT-PCR Buffer III, 0.4 µL each of 10 µM primers (Table S1), 0.25µL of 10.2 µM Taqman
178 Probe, 0.4 µL of 50X ROX Reference Dye II, 0.4 µL of PrimeScript RT enzyme Mix II, 0.4 µL
179 of TaKaRa Ex Taq HS, and 5.75 µL of RNase free water. The conditions consisted of 1 cycle of
180 5 min at 42 °C, 10 sec at 95 °C and followed by 45 cycles of 5 s at 95 °C, 34 s at 55 °C for H1N1
181 or 58 °C for H3N2 and B. The result was analyzed using QuantStudio (Thermo Fisher Scientific,
182 Massachusetts, USA), in which a cycle threshold value (Ct-value) < 40 was defined as a
183 positive result.

184 If the results of TRCsatFLU were different from those of RT-PCR, the TRC and RT-PCR
185 products were analyzed by sequencing according to the Influenza Diagnosis Manual 4th edition
186 (National Institute of Infectious Diseases, 2019).[11] In brief, positive samples were purified

187 using QIAquick PCR Purification kit (Qiagen, Hilden, Germany). Sequencing employed the ABI
188 Big Dye Terminator system (ThermoFisher Scientific, Waltham, MA, USA). It was performed at
189 a contract sequencing facility (FASMAC Co., Ltd. Kanagawa, Japan). For each sequencing
190 reaction, 50 ng template and 3.2 pmol primers (Table S1) were used.

191

192 *Statistical analysis*

193 All statistical analyses were performed using R (the R Foundation for Statistical Computing,
194 Vienna, Austria; version 4.0.3). Fisher's exact test was used to compare categorical variables and
195 the Mann–Whitney U test was used to compare continuous variables. The statistical significance
196 level was set at $p < 0.05$. The sensitivity (Se), specificity (Sp), positive predictive value (PPV),
197 and negative predictive value (NPV) of the TRCsatFLU against the combined results of RT-PCR
198 and sequencing were calculated with 95% confidence intervals (95% CI) as in the previous study.
199 [5]

200

201 **Results**

202 *Patient characteristics*

203 During the study period, 286 patients with ILI participated. Excluded patients and samples were
204 shown in Fig1: one patient was excluded due to withdrawal of consent; 11 nasopharyngeal swabs
205 were excluded due to testing protocol deviation that mixed nasopharyngeal swabs with 1mL
206 extraction buffer for 10 sec, not 5 sec; 40 patients were excluded due to failure of the freezer at
207 the clinic where the samples were stored. Finally, 233 nasopharyngeal swabs and 213 gargle
208 samples obtained from 244 patients were evaluated. Patient characteristics are shown in Table 1.
209 The average age of the patients was 39.3 ± 21.2 . The proportion of patients with underlying

210 diseases and a history of influenza vaccination was 33.2% and 50.0%, respectively. Of the
211 patients, 68.9% visited a hospital within 24 h of symptom onset. The most common symptoms
212 were fever (93.0%), fatigue (79.5%), and nasal discharge (64.8%). In the clinical diagnosis based
213 on history, physical findings, and the results of DIAs, 44.3% of the patients were diagnosed with
214 influenza and 43.0% were diagnosed with acute upper respiratory infection. All patients in whom
215 gargle samples were not collected were children. The average age of the patients was 2.9, and
216 most of them (26/31) were under the age of 5.

217

218 *Detection of influenza by TRCsatFLU in nasopharyngeal swabs and gargle samples*

219 The results of the TRCsatFLU and RT-PCR are shown in Table 2. Influenza was detected in
220 nasopharyngeal swabs and gargle samples using TRCsatFLU in 41.6% and 46.5% of patients,
221 respectively. The positive rate for influenza was highest at 24–48 h after the onset of symptoms
222 in both types of specimens (Fig. 2). Compared to DIAs, the positive rate for influenza within 6 h
223 after the onset of symptoms in TRCsatFLU and RT-PCR in nasopharyngeal swabs was two times
224 higher than that in DIAs (Fig. 2A). There were 14 cases with a clinical diagnosis of influenza
225 despite negative DIAs; influenza was detected in 5 of 14 nasopharyngeal swabs and 4 of 13
226 gargle samples by TRCsatFLU (Table S2). Additionally, influenza was detected by TRCsatFLU
227 in 6 nasopharyngeal swabs and 10 gargle samples collected from the patients diagnosed as other
228 than influenza (Table S2).

229

230 *Performance of TRCsatFLU on the detection of influenza*

231 Four nasopharyngeal swabs showed different results in RT-PCR and TRCsatFLU: one tested
232 positive for influenza A(H1N1)pdm09 only with RT-PCR; two and one tested positive for

233 influenza A and B, respectively, only with TRCsatFLU. In those four samples, influenza B and
234 influenza A(H1N1)pdm09 were detected by sequencing in one and three samples, respectively.
235 Based on the combined RT-PCR and sequencing results, the Se, Sp, PPV, and NPV of
236 TRCsatFLU in nasopharyngeal swabs were 0.990, 1.000, 1.000, and 0.993, respectively (Table
237 3).

238 Five gargle samples showed different results in RT-PCR and TRCsatFLU: three tested positives
239 for influenza A(H1N1)pdm09 only with RT-PCR, and two tested positive for influenza A only
240 with TRCsatFLU. Influenza A(H3N2) was detected by sequencing in one of the samples that
241 tested positive only with TRCsatFLU, and influenza A(H1N1)pdm09 was detected in all other
242 samples. Based on the combined RT-PCR and sequencing results, the Se, Sp, PPV, and NPV of
243 TRCsatFLU in nasopharyngeal swabs were 0.971, 1.000, 1.000, and 0.974, respectively (Table
244 3).

245

246 *Comparison of TRCsatFLU results between nasopharyngeal swabs and gargle samples*

247 We evaluated TRCsatFLU results in nasopharyngeal swabs and gargle samples collected from
248 the same patients. Of 202 patients, 86 were positive for influenza in both specimens. However,
249 14 had different results between nasopharyngeal swabs and gargle samples: seven tested positive
250 for influenza A only in nasopharyngeal swabs, one tested positive for influenza B only in
251 nasopharyngeal swabs, and six patients tested positive for influenza A only in gargle samples.

252 In the patients who tested positive for influenza only in nasopharyngeal swabs, the percentage of
253 fever and headache, the percentage of diagnosing influenza, the influenza-positive rate by DIAs
254 and RT-PCR in nasopharyngeal swabs, and the influenza-positive rate by RT-PCR in gargle
255 samples were significantly lower than the patients who tested positive for influenza in both

256 samples (Table 4). In the patients who tested positive for influenza only in gargle samples, the
257 percentage of patients who visited the medical facilities within 6 h since the onset of symptoms
258 was significantly higher than those who tested positive for influenza in both samples (Table 4).
259 Additionally, the percentage of diagnosing influenza, the influenza-positive rate by DIAs and
260 RT-PCR in nasopharyngeal swabs were significantly lower in the patients who tested positive for
261 influenza only in gargle samples than those in the patients who tested positive for influenza in
262 both samples (Table 4). However, there was no difference between the patients who tested
263 positive for influenza only in nasopharyngeal swabs and only in gargle samples.

264

265 **Discussion**

266 TRCsatFLU showed greater sensitivity and specificity in both nasopharyngeal swabs and gargle
267 samples compared to the combined RT-PCR and sequencing. The sensitivity/specificity of the
268 TRCsatFLU in nasopharyngeal swabs and gargle samples were 0.990/1.000 and 0.971/1.000,
269 respectively, which are similar to those of the previous single-center study (1.000/1.000 and
270 0.946/1.000, respectively). [5] We conducted this study by adding seven clinics to the hospital
271 that participated in the previous study. Therefore, there were differences in patient backgrounds
272 between this study and the previous study. The average age in this study was ten years younger
273 than that in the previous study because only this study included children. In addition, the
274 percentages of patients with symptoms such as fever, fatigue, nasal discharge, headache, sore
275 throat, arthralgia, and myalgia in this study were higher than those in the previous study. Fewer
276 patients visited clinics and hospitals 72 hours after symptom onset compared to those in the
277 previous study (2.9% versus 13.8%), which might have influenced the difference. The proportion
278 of influenza variants was also different between the two studies. In the previous study, the most

279 detected variant was influenza B, and the most detected influenza A variant was. In contrast, in
280 this study, the most detected variant was influenza A(H1N1)pdm09, and influenza B and
281 A(H3N2) were detected from only one patient each. Thus, despite differences in patient
282 backgrounds and influenza variants, the TRCsatFLU showed the same test performance in both
283 studies.

284 TRCsatFLU can detect influenza A and B within 15 min. The most common RIDTs are antigen
285 tests using immunochromatography in nasopharyngeal swabs. However, since conventional
286 antigen tests have very low sensitivity in the early stages of influenza, [1] in this study,
287 commercially available high-sensitivity DIAs using silver amplification immunochromatography
288 [10] were used at clinics and hospitals for clinical diagnosis. However, the positive rate for
289 influenza in DIAs was obviously lower than that of TRCsatFLU in this study. Notably, in
290 patients who visited clinics or hospitals within 6 hours from the onset of symptoms, the positive
291 rate for influenza in DIAs was half of that for TRCsatFLU. In addition, there were 14 cases with
292 a clinical diagnosis of influenza despite negative DIAs. Among them, influenza was detected in 5
293 of 14 nasopharyngeal swabs and 4 of 13 gargle samples by TRCsatFLU. Those results are
294 similar to the results of a multicenter study that we conducted at the same time as this study. In
295 the study, we compared cobas® Liat® PCR System (Liat) and DIAs, and Liat showed a higher
296 positive rate than DIAs (51.6% versus 40.7%), and the difference was evident within 18h from
297 the onset of symptoms. [12] Since other previous studies also reported a higher sensitivity of
298 molecular POC tests compared to DIAs, [2,13,14] molecular POC tests, including TRCsatFLU,
299 can contribute to the accurate diagnosis of influenza.

300 There are several rapid RT-PCR technologies for the detection of influenza, such as Liat, ID
301 NOW (formerly Alere™ i), and GeneXpert Xpress (Xpert). Some multicenter studies have

302 reported their performance for detecting influenza: the sensitivity/specificity of Liat, ID NOW,
303 and Xpert for influenza A and B was reported as 0.996/0.975 and 0.993/0.997, 0.978–
304 0.993/0.966–0.981 and 0.929–0.976/0.983–1.000, and 0.953–1.000/0.948–1.000 and 0.938–
305 1.000/0.995–1.000. [15–20] Compared to the results of these previous studies, TRCsatFLU
306 showed comparable sensitivity and specificity in nasopharyngeal swabs. TRCsatFLU has a
307 unique feature: it can detect influenza in gargle samples with simple sample preparation without
308 purification. In this study and previous single-center studies, TRCsatFLU showed great
309 sensitivity and specificity in gargle samples.[5] Some studies have reported the performance of
310 molecular POC tests on gargle samples, and the sensitivity of Xpert and Liat for influenza
311 detection in gargle samples is 0.917 (11/12 samples) and 1.000 (15/15 samples), respectively,
312 compared to in-house RT-PCR.[21,22] In addition to gargle samples, several non-
313 nasopharyngeal swab specimens, such as nasal aspirate-wash, nasopharyngeal aspirate, throat
314 swabs, and saliva have been evaluated using molecular POC tests. The sensitivity of molecular
315 POC tests in the nasal aspirate wash, nasopharyngeal aspirate, throat swabs, and saliva was
316 0.900–1.000, 0.980–1.000, 0.75–0.83, and 0.750–0.918, respectively.[19,23,24] Among these
317 samples, only nasopharyngeal aspirate showed high sensitivity comparable to gargle samples in
318 this study.[23] The results in previous studies [5,19,21–24] and this study indicate that the gargle
319 sample is an excellent specimen for detecting influenza by molecular POC tests. However, the
320 sample preparation method was not described in the previous studies that evaluated the gargle
321 samples using Xpert and Liat. [21,22] In addition, molecular POC tests other than TRCsatFLU
322 do not officially designate gargle samples as specimens. Therefore, further studies are needed to
323 determine whether gargle samples can be used as specimens in molecular POC tests other than
324 TRCsatFlu.

325 In this study, the positive rate for influenza in TRCsatFLU was higher in the gargle samples
326 (46.5%) than in nasopharyngeal swabs (41.6%). However, in the 202 patients for whom both
327 samples were taken, the positive rate was slightly lower in gargle samples (45.5%) than in
328 nasopharyngeal swabs (46.5%). Among the 202 patients, 8 were positive for influenza only in
329 nasopharyngeal swabs, and 6 were positive for influenza only in gargle samples, but there were
330 no significant differences in patient background between them. Therefore, it is not clear which
331 cases of gargle samples should be used in preference to nasopharyngeal swabs. When compared
332 to patients who tested positive for influenza in both samples, the influenza-positive rate by DIAs
333 and RT-PCR and the percentage of diagnosing influenza were significantly lower in patients who
334 tested positive for influenza only in either of the samples. These results suggest that the viral
335 load in the sample was low in the patients who tested positive for influenza only in either of the
336 samples.

337 This study had some limitations. We could only collect samples for one season because of the
338 COVID-19 pandemic, as described in the Materials and Methods section. Therefore, we
339 analyzed the data collected from fewer patients than initially planned. In addition, only one
340 patient with an influenza B infection was included in this study. In a previous study, the
341 TRCsatFLU showed high sensitivity and specificity for influenza B in nasopharyngeal swabs [5]
342 but its performance in gargle samples remains unknown. In this study, TRCsatFLU has not been
343 compared with other molecular POC tests. Thus, a comparative study is needed to determine if
344 TRCsatFLU performs as well as other molecular POC tests.

345

346 **Conclusions**

347 The novel molecular POC test, TRCsatFLU, showed great sensitivity and specificity for the

348 detection of influenza. Since TRCsatFLU detects influenza in gargle samples collected by the
349 patient, it can contribute to reducing the exposure risk to pathogens during sample collection by
350 healthcare professionals.

351

352 **Declarations**

353 **Ethics approval:** This study was approved by the ethics committee of Nagasaki University
354 Hospital (approval number:19121603). : Before sample collection, written informed consent for
355 the participation of this study was obtained from all participants.

356 **Consent for publication:** Before sample collection, written informed consent for the publication
357 of this study was obtained from all participants.

358 **Availability of data and materials:** The derived data supporting the findings of this study are
359 presented in this paper, supplementary Table1 and 2, and metadata file.

360 **Competing interests:** The authors declare no conflicts of interest directly relevant to the content
361 of this article.

362 **Funding:** Tosoh Corporation funded the study. The sponsor performed RT-PCR, TRC, and
363 sequencing for influenza, but had no control over the interpretation, writing, or publication of
364 this work.

365 **Authors' contributions:** All the authors were involved in the study design. TU, TI, CY, YN,
366 YO, KH, KH, and AT acquired the samples and data. NK, KI, HK, and KY were involved in
367 data interpretation and analysis. NK wrote the original manuscript, and all authors revised and
368 approved the manuscript for publication.

369 **Acknowledgements:** none

370

371
372

373 **References**

- 374
- 375 1. Chartrand C, Leeflang MMG, Minion J, Brewer T, Pai M. Accuracy of rapid influenza
- 376 diagnostic tests: A meta-analysis. *Ann Intern Med.* American College of Physicians;
- 377 2012;156:500–11.
- 378 2. Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic accuracy of
- 379 novel and traditional rapid tests for influenza infection compared with reverse transcriptase
- 380 polymerase chain reaction. *Ann Intern Med.* *Ann Intern Med*; 2017;167:395–409.
- 381 3. Drouillon V, Delogu G, Dettori G, Lagrange PH, Benecchi M, Houriez F, et al. Multicenter
- 382 Evaluation of a Transcription-Reverse Transcription Concerted Assay for Rapid Detection of
- 383 *Mycobacterium tuberculosis* Complex in Clinical Specimens. *J Clin Microbiol.* American
- 384 Society for Microbiology Journals; 2009;47:3461–5.
- 385 4. Mazzarelli A, Cannas A, Venditti C, D'Arezzo S, De Giuli C, Truffa S, et al. Clinical
- 386 evaluation of TRCReady M.TB for rapid automated detection of *M. tuberculosis* complex in
- 387 respiratory samples. *Int J Tuberc Lung Dis.* *Int J Tuberc Lung Dis*; 2019;23:260–4.
- 388 5. Kaku N, Hashiguchi K, Akamatsu N, Wakigawa F, Matsuda J, Komaru K, et al. Evaluation of
- 389 a novel rapid TRC assay for the detection of influenza using nasopharyngeal swabs and gargle
- 390 samples. *Eur J Clin Microbiol Infect Dis.* *Eur J Clin Microbiol Infect Dis*; 2021;40:1743–8.
- 391 6. Kaku N, Ota K, Sasaki D, Akamatsu N, Uno N, Sakamoto K, et al. Had COVID-19 spread in
- 392 the community before the first confirmed case in Nagasaki, Japan? *Microbes Infect.* *Microbes*
- 393 *Infect*; 2021;23:104812.
- 394 7. Kaku N, Nishimura F, Shigeishi Y, Tachiki R, Sakai H, Sasaki D, et al. Performance of anti-
- 395 SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective
- 396 study in outbreak on a cruise ship. *PLoS One.* *Public Library of Science*; 2021;16:e0257452.

- 397 8. Ota K, Yanagihara K, Sasaki D, Kaku N, Uno N, Sakamoto K, et al. Detection of SARS-CoV-
398 2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients,
399 comparative analysis with matched nasopharyngeal samples. *PLoS One. Public Library of*
400 *Science*; 2021;16:e0252964.
- 401 9. World Health Organization. World Health Organization Global Epidemiological Surveillance
402 Standards for Influenza [Internet]. 2013. Available from:
403 <https://www.who.int/publications/i/item/9789241506601>
- 404 10. Mitamura K, Shimizu H, Yamazaki M, Ichikawa M, Nagai K, Katada J, et al. Clinical
405 evaluation of highly sensitive silver amplification immunochromatography systems for rapid
406 diagnosis of influenza. *J Virol Methods*. 2013;194:123–8.
- 407 11. National Institute of Infectious Diseases. Manual for diagnosis of influenza [Internet]. 4th ed.
408 Tokyo; 2019. p. 24–57. Available from: [https://www.niid.go.jp/niid/images/lab-](https://www.niid.go.jp/niid/images/lab-manual/influenza20190116.pdf)
409 [manual/influenza20190116.pdf](https://www.niid.go.jp/niid/images/lab-manual/influenza20190116.pdf)
- 410 12. Kaku N, Kodama H, Akamatsu N, Ota K, Kosai K, Morinaga Y, et al. Multicenter evaluation
411 of molecular point-of-care testing and digital immunoassays for influenza virus A/B and
412 respiratory syncytial virus in patients with influenza-like illness. *J Infect Chemother. Elsevier*;
413 2021;27:820–5.
- 414 13. Kanwar N, Michael J, Doran K, Montgomery E, Selvarangan R. Comparison of the ID Now
415 Influenza A & B 2, Cobas Influenza A/B, and Xpert Xpress Flu Point-of-Care Nucleic Acid
416 Amplification Tests for Influenza A/B Virus Detection in Children. *J Clin Microbiol. J Clin*
417 *Microbiol*; 2020;58.
- 418 14. Sato Y, Nirasawa S, Saeki M, Yakuwa Y, Ono M, Kobayashi R, et al. Comparative study of
419 rapid antigen testing and two nucleic acid amplification tests for influenza virus detection. *J*

- 420 Infect Chemother; 2022;28:1033–6.
- 421 15. Gibson J, Schechter-Perkins EM, Mitchell P, Mace S, Tian Y, Williams K, et al. Multi-center
422 evaluation of the cobas® Liat® Influenza A/B & RSV assay for rapid point of care
423 diagnosis. *J Clin Virol*. *J Clin Virol*; 2017;95:5–9.
- 424 16. Hassan F, Crawford J, Bonner AB, Ledebor NA, Selvarangan R. Multicenter evaluation of
425 the Alere™ i influenza A&B assay using respiratory specimens collected in viral transport media.
426 *Diagn Microbiol Infect Dis*. *Diagn Microbiol Infect Dis*; 2018;92:294–8.
- 427 17. Bell J, Bonner A, Cohen DM, Birkhahn R, Yogev R, Triner W, et al. Multicenter clinical
428 evaluation of the novel Alere™ i Influenza A&B isothermal nucleic acid amplification test. *J*
429 *Clin Virol*. *J Clin Virol*; 2014;61:81–6.
- 430 18. Wolters F, Grünberg M, Huber M, Kessler HH, Prüller F, Saleh L, et al. European
431 multicenter evaluation of Xpert® Xpress SARS-CoV-2/Flu/RSV test. *J Med Virol*. *J Med Virol*;
432 2021;93:5798–804.
- 433 19. Novak-Weekley S, Marlowe EM, Poulter M, Dwyer D, Speers D, Rawlinson W, et al.
434 Evaluation of the Cepheid Xpert Flu Assay for rapid identification and differentiation of
435 influenza A, influenza A 2009 H1N1, and influenza B viruses. *J Clin Microbiol*. *J Clin*
436 *Microbiol*; 2012;50:1704–10.
- 437 20. Cohen DM, Kline J, May LS, Harnett GE, Gibson J, Liang SY, et al. Accurate pcr detection
438 of influenza a/b and respiratory syncytial viruses by use of cepheid xpert flu+rsv xpress assay in
439 point-of-care settings: Comparison to prodesse proflu+. *J Clin Microbiol*. *J Clin Microbiol*;
440 2018;56.
- 441 21. Bennett S, MacLean A, Gunson R. Verification of Cepheid Xpert Xpress Flu/RSV assay for
442 use with gargle samples, sputa and endotracheal secretions. 2019;101:114–5.

- 443 22. Goldstein EJ, Gunson RN. In-house validation of the cobas Liat influenza A/B and RSV
444 assay for use with gargles, sputa and endotracheal secretions. *J Hosp Infect. J Hosp Infect*;
445 2019;101:289–91.
- 446 23. To KKW, Yip CCY, Lai CYW, Wong CKH, Ho DTY, Pang PKP, et al. Saliva as a
447 diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic
448 validity study. *Clin Microbiol Infect. Clin Microbiol Infect*; 2019;25:372–8.
- 449 24. Davis S, Allen AJ, O’Leary R, Power M, Price DA, Simpson AJ, et al. Diagnostic accuracy
450 and cost analysis of the Alere™ i Influenza A&B near-patient test using throat swabs. *J Hosp
451 Infect. J Hosp Infect*; 2017;97:301–9.
- 452 25. Frazee BW, Rodríguez-Hoces de la Guardia A, Alter H, Chen CG, Fuentes EL, Holzer AK,
453 et al. Accuracy and Discomfort of Different Types of Intranasal Specimen Collection Methods
454 for Molecular Influenza Testing in Emergency Department Patients. *Ann Emerg Med. Ann
455 Emerg Med*; 2018;71:509-517.e1.
- 456 26. Malecki M, Lüsebrink J, Teves S, Wendel AF. Pharynx gargle samples are suitable for
457 SARS-CoV-2 diagnostic use and save personal protective equipment and swabs. *Infect. Control
458 Hosp. Epidemiol. Infect Control Hosp Epidemiol*; 2021. p. 248–9.
- 459

460 **Tables**

Table 1. Patient characteristics

Characteristic	All		Nasopharyngeal swabs and gargle samples		Nasopharyngeal swabs only		Gargle samples only	
	N=244		N=202		N=31		N=11	
	N	(%)	N	(%)	N	(%)	N	(%)
Age (average ± S.D.)	39.3	± 21.2	44.6	± 16.6	2.9	± 2.9	43.5	± 24.0
Under 16 years old	37	(15.2%)	4	(2.0%)	31	(100%)	2	(18.2%)
Gender, female	138	(56.6%)	119	(58.9%)	14	(45.2%)	5	(45.5%)
Underlying diseases	81	(33.2%)	75	(37.1%)	3	(9.7%)	3	(27.3%)
History of								
Influenza vaccination	122	(50.0%)	102	(50.5%)	14	(45.2%)	6	(54.5%)
Time since onset of symptoms								
0 - 6 h	33	(13.5%)	26	(12.9%)	5	(16.1%)	2	(18.2%)
6 - 12 h	31	(12.7%)	21	(10.4%)	9	(29.0%)	1	(9.1%)
12 - 24 h	104	(42.6%)	86	(42.6%)	13	(41.9%)	5	(45.5%)
24 - 48 h	45	(18.4%)	41	(20.3%)	3	(9.7%)	1	(9.1%)
48 - 72 h	21	(8.6%)	20	(9.9%)	1	(9.7%)	0	(0.0%)

72 h -	7 (2.9%)	6 (3.0%)	0 (0.0%)	1 (9.1%)
Unknown	3 (1.2%)	2 (1.0%)	0 (0.0%)	1 (9.1%)
Symptoms				
Fever	227 (93.0%)	186 (92.1%)	31 (100%)	10 (90.9%)
Fatigue	194 (79.5%)	177 (87.6%)	1 (3.2%)	8 (72.7%)
Nasal discharge	158 (64.8%)	128 (63.4%)	20 (64.5%)	10 (90.9%)
Cough	157 (64.3%)	137 (67.8%)	18 (58.1%)	2 (18.2%)
Headache	152 (62.3%)	144 (71.3%)	1 (3.2%)	7 (63.6%)
Sore throat	150 (61.5%)	141 (69.8%)	2 (6.5%)	7 (63.6%)
Arthralgia	129 (52.9%)	124 (61.4%)	0 (0.0%)	5 (45.5%)
Myalgia	97 (39.8%)	92 (45.5%)	9 (29.0%)	4 (36.4%)
Diarrhea	15 (6.1%)	14 (6.9%)	1 (3.2%)	1 (9.1%)
Nausea	13 (5.3%)	11 (5.4%)	0 (0.0%)	1 (9.1%)
Results of influenza antigen test using silver amplification immunochromatography				
Influenza A	93 (38.1%)	84 (41.6%)	5 (16.1%)	4 (36.4%)
Influenza B	1 (0.4%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
Negative	150 (61.5%)	117 (57.9%)	26 (83.9%)	7 (63.6%)
Clinical Diagnosis				
Influenza	108 (44.3%)	98 (48.5%)	6 (19.4%)	4 (36.4%)
Acute upper respiratory infection	105 (43.0%)	77 (38.1%)	21 (67.7%)	7 (63.6%)

Acute bronchitis	17 (7.0%)	14 (6.9%)	3 (9.7%)	0 (0.0%)
Others	14 (5.7%)	13 (6.4%)	1 (3.2%)	0 (0.0%)

S.D., standard deviation

461
462
463

Table 2. Results of TRCsatFLU

	Nasopharyngeal swabs		Gargle samples	
	(N=233)		(N=213)	
	N	(%)	N	(%)
TRCsatFLU				
Influenza A	97	(41.6%)	99	(46.5%)
Influenza B	1	(0.4%)	0	(0.0%)
Negative	135	(57.9%)	114	(53.5%)
RT-PCR				
Influenza A(H1N1)pdm09	96	(41.2%)	100	(46.9%)
Influenza B	0	(0.0%)	0	(0.0%)
Negative	137	(58.8%)	113	(53.1%)

464
465

Table 3. Performance of TRCsatFLU in nasopharyngeal swabs and gargle samples

	Nasopharyngeal swabs		Gargle samples	
	(N=233)		(N=213)	
True-positive	98		99	
True-negative	134		111	
False-positive	0		0	

False-negative	1	3
Se (95% CI)	0.990 (0.945-1.000)	0.971 (0.916-0.994)
Sp (95% CI)	1.000 (0.959-1.000)	1.000 (0.951-1.000)
PPV (95% CI)	1.000 (0.945-1.000)	1.000 (0.951-1.000)
NPV (95% CI)	0.993 (0.959-1.000)	1.000 (0.925-0.995)

CI, confidence

466
467

Table 4. Characteristics of patients with different results between nasopharyngeal swabs and gargle sample

	Positive in both samples		Positive only in nasopharyngeal swabs		<i>P</i> value compared to positive in both samples	Positive only in gargle samples		<i>P</i> value compared to positive in both samples	<i>P</i> value compared positive only in nasopharyngeal swabs and only in gargle samples
	(N=86)		(N=8)			(N=6)			
	N	(%)	N	(%)		N	(%)		
Age (average ± S.D)	44.9	± 22.9	50.9	± 22.9	NS	41.3	± 10.9	NS	NS
Under 16 years old	3	(3.5%)	1	(12.5%)	NS	0	(0.0%)	NS	NS
Gender, female	53	(61.6%)	5	(62.5%)	NS	1	(16.7%)	0.078	0.138
Underlying diseases	29	(33.7%)	4	(50.0%)	NS	2	(33.3%)	NS	NS
History of Influenza vaccination	33	(38.4%)	4	(50.0%)	NS	2	(33.3%)	NS	NS
Time since onset of symptoms									
0–6 h	6	(7.0%)	2	(25.0%)	0.137	3	(50.0%)	0.011	NS
6-12 h	6	(7.0%)	1	(12.5%)	NS	0	(0.0%)	NS	NS
12–24 h	43	(50.0%)	1	(12.5%)	0.063	3	(50.0%)	NS	1
24–48 h	21	(24.4%)	3	(37.5%)	NS	0	(0.0%)	NS	0.245
48–72 h	7	(8.1%)	1	(12.5%)	NS	0	(0.0%)	NS	0.209
72+ h	2	(2.3%)	0	(0.0%)	NS	0	(0.0%)	NS	NS
Unknown	1	(1.2%)	0	(0.0%)	NS	0	(0.0%)	NS	NS
Symptoms									
Fever	82	(95.3%)	5	(62.5%)	0.012	6	(100%)	NS	0.209
Fatigue	77	(89.5%)	8	(100%)	NS	5	(83.3%)	NS	NS
Nasal discharge	54	(62.8%)	5	(62.5%)	NS	3	(50.0%)	NS	NS

Cough	70	(81.4%)	8	(100%)	NS	5	(83.3%)	NS	NS
Headache	70	(81.4%)	4	(50.0%)	0.060	5	(83.3%)	NS	NS
Sore throat	59	(68.6%)	7	(87.5%)	NS	5	(83.3%)	NS	NS
Arthralgia	58	(67.4%)	5	(62.5%)	NS	4	(66.7%)	NS	NS
Myalgia	48	(55.8%)	4	(50.0%)	NS	1	(16.7%)	0.093	NS
Diarrhea	5	(5.8%)	0	(0.0%)	NS	1	(16.7%)	NS	NS
Nausea	4	(4.7%)	0	(0.0%)	NS	0	(0.0%)	NS	NS
Results of DIAs									
Influenza A	80	(93.0%)	3	(37.5%)	<0.001	1	(16.7%)	<0.001	NS
Negative	6	(7.0%)	5	(62.5%)		5	(83.3%)		
Clinical Diagnosis									
Influenza	83	(96.5%)	5	(62.5%)	0.007	2	(33.3%)	<0.001	0.138
Acute upper respiratory infection	3	(3.5%)	1	(12.5%)	NS	3	(50.0%)	0.003	0.245
Acute bronchitis	0	(0.0%)	2	(25.0%)	0.006	1	(16.7%)	0.065	NS
Results of RT-PCR in nasopharyngeal swabs									
Influenza A(H1N1)pdm09	85	(98.8%)	6	(75.0%)	0.018	1	(16.7%)	<0.001	0.103
Negative	1	(1.1%)	2	(25.0%)		5	(83.3%)		
Results of RT-PCR in gargle samples									
Influenza A(H1N1)pdm09	85	(98.8%)	2	(25.0%)	<0.001	5	(83.3%)	0.127	0.103
Negative	1	(1.1%)	6	(75.0%)		1	(16.7%)		

NS, not significant ($P > 0.2$)

469 **Figure legends**

470 **Figure 1. Participant flow diagram**

471 Participant flow diagram showing progression through phases of prospective observational study.

472

473 **Figure 2. Positive rate of influenza in each test by time since onset of symptoms**

474 Nasopharyngeal swabs were collected from all patients using two swabs (A). Gargle samples

475 were collected from patients whom the physician judged fit to perform gargling (B). A highly

476 sensitive automated antigen test was performed using silver amplification

477 immunochromatography for influenza (FUJI DRI-CHEM IMMUNO AG Cartridge FluAB;

478 Fujifilm, Kanagawa, Japan) at clinics and hospitals. Nasopharyngeal swabs and gargle samples

479 for TRCsatFLU and RT-PCR were stored at -20°C until further analysis. The samples were

480 transferred to Tosoh Corporation to perform TRCsatFLU and RT-PCR.

481




Figure 1. Participant flow diagram

Participant flow diagram showing progression through phases of prospective observational study.




Figure 2. Positive rate of influenza in each test by time since onset of symptoms

Nasopharyngeal swabs were collected from all patients using two swabs (A). Gargle samples were collected from patients whom the physician judged fit to perform gargling (B). A highly sensitive automated antigen test was performed using silver amplification immunochromatography for influenza (FUJI DRI-CHEM IMMUNO AG Cartridge FluAB; Fujifilm, Kanagawa, Japan) at clinics and hospitals. Nasopharyngeal swabs and gargle samples for TRC and RT-PCR were stored at -20°C until further analysis. The samples were transferred to Tosoh Corporation to perform TRCsatFLU and RT-PCR.